tazobactam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 2572 89786-04-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tazobactam
  • tazobactam sodium
  • YTR-830
  • YTR 830
A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.
  • Molecular weight: 300.29
  • Formula: C10H12N4O5S
  • CLOGP: -0.65
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 122.46
  • ALOGS: -1.50
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 77 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 66.49 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.26 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.81 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.97 hours Lombardo F, Berellini G, Obach RS
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.866 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.377 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.166 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 3.373 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 73.050 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 43.760 % Moderate 0.76
herg hERG pIC50 4.535 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 1.038 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 3.890 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 45.240 % Moderate 0.76
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1 35
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6,TEK,TGFBR1 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.348 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 12.972 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 68.680 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.679 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 67.980 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 2.716 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.990 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 51.040 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 855.067 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 1993 FDA
Sept. 18, 2015 EMA MERCK SHARP & DOHME B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 150.50 19.75 146 9609 208579 90410113
Sepsis 133.77 19.75 128 9627 179686 90439006
Pseudomonal sepsis 99.83 19.75 31 9724 4271 90614421
Acute kidney injury 84.25 19.75 135 9620 320252 90298440
Nail bed inflammation 82.32 19.75 22 9733 1779 90616913
Hemianopia 79.16 19.75 22 9733 2060 90616632
Nasal mucosal disorder 76.97 19.75 21 9734 1836 90616856
Respiratory failure 76.26 19.75 78 9677 118340 90500352
Skin fissures 71.89 19.75 38 9717 20771 90597921
Pleural effusion 68.92 19.75 72 9683 111919 90506773
Leukopenia 67.87 19.75 68 9687 100642 90518050
Congenital cytomegalovirus infection 67.36 19.75 12 9743 138 90618554
Multiple organ dysfunction syndrome 65.15 19.75 56 9699 68280 90550412
Brain oedema 63.63 19.75 33 9722 17352 90601340
Renal failure 62.96 19.75 74 9681 130933 90487759
Pancytopenia 62.96 19.75 71 9684 120192 90498500
Pyrexia 59.87 19.75 181 9574 660304 89958388
Vascular device infection 59.57 19.75 28 9727 11924 90606768
Candida infection 59.33 19.75 40 9715 34017 90584675
Eosinophilia 58.22 19.75 37 9718 28496 90590196
Deafness congenital 55.97 19.75 10 9745 117 90618575
Varicose vein 55.39 19.75 23 9732 7304 90611388
Febrile neutropenia 54.84 19.75 76 9679 158273 90460419
White blood cell count decreased 54.60 19.75 78 9677 167031 90451661
Rash maculo-papular 52.71 19.75 40 9715 40893 90577799
Toxic skin eruption 52.21 19.75 28 9727 15746 90602946
Disseminated intravascular coagulation 51.75 19.75 31 9724 21507 90597185
Septic shock 51.57 19.75 54 9701 84106 90534586
Metastases to lymph nodes 51.02 19.75 25 9730 11664 90607028
Paronychia 50.16 19.75 22 9733 7984 90610708
Platelet count decreased 47.81 19.75 66 9689 136903 90481789
Dermatitis exfoliative generalised 47.21 19.75 19 9736 5574 90613118
Toxic epidermal necrolysis 46.84 19.75 34 9721 32494 90586198
Arthralgia 45.00 19.75 14 9741 778508 89840184
Metastases to central nervous system 44.10 19.75 26 9729 17516 90601176
Haemoglobin decreased 43.50 19.75 69 9686 161887 90456805
Blood creatinine increased 43.36 19.75 54 9701 101332 90517360
Premature baby 40.23 19.75 28 9727 25049 90593643
Tubulointerstitial nephritis 39.96 19.75 28 9727 25315 90593377
Joint swelling 39.88 19.75 4 9751 503296 90115396
Rash morbilliform 38.60 19.75 15 9740 4014 90614678
Streptococcal sepsis 36.68 19.75 14 9741 3570 90615122
Alopecia 36.58 19.75 5 9750 495066 90123626
Hydronephrosis 35.49 19.75 20 9735 12382 90606310
Anaemia 35.00 19.75 100 9655 352702 90265990
Drug reaction with eosinophilia and systemic symptoms 34.69 19.75 32 9723 42726 90575966
Prothrombin time prolonged 34.18 19.75 18 9737 9754 90608938
Agranulocytosis 33.99 19.75 29 9726 34973 90583719
Restlessness 33.47 19.75 29 9726 35691 90583001
Abdominal discomfort 32.60 19.75 6 9749 477322 90141370
Nephropathy toxic 32.40 19.75 19 9736 12669 90606023
Heparin-induced thrombocytopenia 31.35 19.75 14 9741 5298 90613394
Hypokalaemia 31.32 19.75 53 9702 131063 90487629
Platelet count increased 30.48 19.75 22 9733 20837 90597855
Streptococcal infection 29.97 19.75 15 9740 7318 90611374
Drug ineffective 28.80 19.75 67 9688 1384231 89234461
Cytomegalovirus infection 27.81 19.75 23 9732 26579 90592113
Drug intolerance 27.76 19.75 7 9748 447584 90171108
Neutropenia 27.58 19.75 69 9686 224835 90393857
Weight increased 26.98 19.75 6 9749 417921 90200771
Foetal growth restriction 26.50 19.75 15 9740 9365 90609327
Acute generalised exanthematous pustulosis 26.05 19.75 17 9738 13686 90605006
Haemolytic anaemia 25.95 19.75 16 9739 11681 90607011
Clostridium difficile colitis 25.67 19.75 22 9733 26684 90592008
Peritonitis 24.79 19.75 19 9736 19686 90599006
Leukocytosis 24.76 19.75 23 9732 30967 90587725
Ascites 24.64 19.75 28 9727 47712 90570980
Bullous erysipelas 24.49 19.75 4 9751 26 90618666
Dizziness 24.16 19.75 17 9738 589267 90029425
Sinusitis 24.09 19.75 4 9751 343084 90275608
Stevens-Johnson syndrome 23.86 19.75 22 9733 29354 90589338
Aspartate aminotransferase increased 23.77 19.75 41 9714 102896 90515796
Systemic lupus erythematosus 23.75 19.75 5 9750 361891 90256801
Linear IgA disease 23.69 19.75 9 9746 2265 90616427
Renal impairment 23.06 19.75 41 9714 105380 90513312
Hypotension 22.89 19.75 82 9673 325315 90293377
Neutrophil count decreased 22.76 19.75 33 9722 71499 90547193
Fall 22.38 19.75 12 9743 481798 90136894
Acute respiratory distress syndrome 22.36 19.75 21 9734 28665 90590027
Blood lactate dehydrogenase increased 22.19 19.75 20 9735 25912 90592780
Musculoskeletal stiffness 21.87 19.75 3 9752 296529 90322163
C-reactive protein increased 21.55 19.75 55 9700 181334 90437358
International normalised ratio increased 21.50 19.75 26 9729 47290 90571402
Perforation 21.16 19.75 8 9747 1986 90616706
Unresponsive to stimuli 20.77 19.75 23 9732 38098 90580594
Blood albumin decreased 20.70 19.75 16 9739 16787 90601905
Abdominal wound dehiscence 20.68 19.75 5 9750 270 90618422
Product contamination microbial 20.48 19.75 5 9750 281 90618411
Clostridial infection 20.48 19.75 10 9745 4626 90614066
Scar pain 20.33 19.75 5 9750 290 90618402
Wound 20.26 19.75 4 9751 302976 90315716
Therapeutic product effect decreased 20.02 19.75 3 9752 277568 90341124

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lymphocyte count abnormal 199.49 17.92 58 13471 2129 42605677
Delusion of grandeur 126.50 17.92 40 13489 1956 42605850
Neutrophil count increased 122.39 17.92 77 13452 19727 42588079
Rhinalgia 117.06 17.92 37 13492 1807 42605999
Thrombocytopenia 107.93 17.92 206 13323 190073 42417733
Affective disorder 93.27 17.92 43 13486 5917 42601889
Platelet count decreased 92.39 17.92 161 13368 138420 42469386
Pyrexia 92.26 17.92 304 13225 393738 42214068
Acute kidney injury 90.11 17.92 288 13241 367049 42240757
Multiple organ dysfunction syndrome 82.64 17.92 126 13403 96909 42510897
Leukopenia 70.71 17.92 102 13427 74644 42533162
Tubulointerstitial nephritis 70.48 17.92 67 13462 31481 42576325
Schizophrenia 70.17 17.92 43 13486 10507 42597299
Choroiditis 68.64 17.92 23 13506 1352 42606454
Neutropenia 67.74 17.92 176 13353 199255 42408551
SARS-CoV-2 test positive 66.27 17.92 38 13491 8222 42599584
Sepsis 62.71 17.92 171 13358 199163 42408643
Extrapyramidal disorder 59.47 17.92 46 13483 16366 42591440
Lymphocyte count 59.08 17.92 14 13515 226 42607580
Hallucination, auditory 50.26 17.92 40 13489 14824 42592982
Lymphocyte count decreased 49.11 17.92 52 13477 27757 42580049
Renal failure 48.89 17.92 127 13402 143599 42464207
Agranulocytosis 46.70 17.92 53 13476 30559 42577247
Clostridial infection 45.61 17.92 23 13506 3851 42603955
Cholestasis 43.63 17.92 53 13476 32826 42574980
Device related sepsis 42.63 17.92 22 13507 3865 42603941
Disseminated intravascular coagulation 41.38 17.92 45 13484 24749 42583057
Dizziness 41.03 17.92 14 13515 249240 42358566
Death 39.88 17.92 55 13474 471130 42136676
Intraocular pressure increased 37.20 17.92 24 13505 6409 42601397
Psychotic disorder 37 17.92 46 13483 29162 42578644
Eosinophilia 35.71 17.92 48 13481 32851 42574955
Renal tubular necrosis 35.42 17.92 36 13493 18318 42589488
Respiratory failure 35.41 17.92 105 13424 128027 42479779
Septic shock 35.33 17.92 85 13444 91587 42516219
Heparin-induced thrombocytopenia 34.23 17.92 23 13506 6574 42601232
Stevens-Johnson syndrome 33.14 17.92 38 13491 22140 42585666
Headache 32.18 17.92 18 13511 239351 42368455
Drug reaction with eosinophilia and systemic symptoms 30.74 17.92 51 13478 42024 42565782
Congenital pneumonia 30.47 17.92 7 13522 98 42607708
Clostridium difficile colitis 29.40 17.92 35 13494 21217 42586589
Uveitis 29.36 17.92 24 13505 9234 42598572
Mucosal inflammation 28.53 17.92 54 13475 49320 42558486
Rash 27.02 17.92 165 13364 276789 42331017
Chills 26.84 17.92 78 13451 93988 42513818
Arthralgia 26.77 17.92 16 13513 205222 42402584
Blood creatinine increased 26.53 17.92 86 13443 109917 42497889
Nephropathy toxic 25.41 17.92 29 13500 16809 42590997
Alopecia 24.84 17.92 38 13491 29238 42578568
Cellulitis 24.68 17.92 58 13471 61527 42546279
Subclavian artery occlusion 24.11 17.92 6 13523 120 42607686
Nephritis 24.06 17.92 15 13514 3774 42604032
Neutrophil count decreased 23.56 17.92 58 13471 63357 42544449
Haemodialysis 23.30 17.92 22 13507 10238 42597568
Bone marrow failure 22.69 17.92 39 13490 33054 42574752
Pneumonia staphylococcal 22.68 17.92 14 13515 3462 42604344
Enterobacter pneumonia 22.62 17.92 8 13521 553 42607253
Weight decreased 22.21 17.92 20 13509 207928 42399878
Alanine aminotransferase increased 22.11 17.92 70 13459 88336 42519470
Eye pain 21.85 17.92 27 13502 17003 42590803
Hepatic failure 21.18 17.92 41 13488 38059 42569747
Blood alkaline phosphatase increased 20.98 17.92 38 13491 33559 42574247
Dialysis 20.42 17.92 22 13507 11964 42595842
Leukocytosis 20.36 17.92 35 13494 29673 42578133
Spontaneous haematoma 20.28 17.92 8 13521 750 42607056
Incorrect dose administered 20.26 17.92 49 13480 52925 42554881
Psychiatric decompensation 20.19 17.92 14 13515 4208 42603598
Weight increased 19.68 17.92 5 13524 107978 42499828
Respiratory distress 19.68 17.92 42 13487 41778 42566028
Visual acuity reduced 19.64 17.92 26 13503 17524 42590282
Gamma-glutamyltransferase increased 19.34 17.92 36 13493 32461 42575345
Pancytopenia 19.10 17.92 81 13448 117662 42490144
Hepatic cytolysis 18.88 17.92 32 13497 26812 42580994
Bacterial sepsis 18.88 17.92 16 13513 6466 42601340
Dyspepsia 18.85 17.92 41 13488 41311 42566495
Insomnia 18.82 17.92 7 13522 118246 42489560
Acute respiratory distress syndrome 18.73 17.92 34 13495 30074 42577732
Autoimmune haemolytic anaemia 18.61 17.92 15 13514 5656 42602150
Drug ineffective 18.44 17.92 121 13408 630076 41977730
Rash erythematous 18.41 17.92 35 13494 32056 42575750
Blood bilirubin increased 18.26 17.92 41 13488 42211 42565595
Product use in unapproved indication 18.23 17.92 19 13510 184437 42423369
Transplant rejection 18.17 17.92 22 13507 13566 42594240

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 204.95 18.37 279 19275 348606 110221139
Acute kidney injury 175.50 18.37 362 19192 635068 109934677
Sepsis 158.65 18.37 239 19315 327107 110242638
Delusion of grandeur 140.09 18.37 39 19515 2221 110567524
Multiple organ dysfunction syndrome 133.69 18.37 149 19405 151561 110418184
Lymphocyte count abnormal 123.94 18.37 36 19518 2390 110567355
Renal failure 120.59 18.37 173 19381 226401 110343344
Pyrexia 116.94 18.37 386 19168 897879 109671866
Leukopenia 114.03 18.37 136 19418 148655 110421090
Tubulointerstitial nephritis 107.96 18.37 84 19470 54200 110515545
Rhinalgia 106.85 18.37 36 19518 3893 110565852
Platelet count decreased 105.51 18.37 164 19390 230279 110339466
Eosinophilia 94.80 18.37 80 19474 57856 110511889
Septic shock 92.28 18.37 126 19428 157402 110412343
Neutropenia 92.20 18.37 204 19350 374416 110195329
Affective disorder 88.16 18.37 42 19512 11199 110558546
Choroiditis 78.24 18.37 23 19531 1592 110568153
Arthralgia 74.01 18.37 23 19531 779609 109790136
Nail bed inflammation 73.05 18.37 23 19531 2007 110567738
Agranulocytosis 72.93 18.37 71 19483 61689 110508056
Neutrophil count increased 71.89 18.37 55 19499 34597 110535148
Nasal mucosal disorder 70.54 18.37 22 19532 1861 110567884
Respiratory failure 69.17 18.37 131 19423 215201 110354544
Drug reaction with eosinophilia and systemic symptoms 67.77 18.37 78 19476 82017 110487728
Clostridial infection 63.40 18.37 28 19526 6274 110563471
Joint swelling 62.55 18.37 4 19550 442841 110126904
Pseudomonal sepsis 62.52 18.37 31 19523 9015 110560730
Schizophrenia 62.16 18.37 42 19512 21784 110547961
Rash maculo-papular 62.08 18.37 71 19483 74151 110495594
Dizziness 62.06 18.37 23 19531 698170 109871575
Heparin-induced thrombocytopenia 61.23 18.37 33 19521 11391 110558354
Pancytopenia 60.60 18.37 122 19432 209491 110360254
SARS-CoV-2 test positive 59.05 18.37 37 19517 16898 110552847
Toxic skin eruption 57.80 18.37 44 19510 27471 110542274
Hemianopia 57.71 18.37 21 19533 2847 110566898
Extrapyramidal disorder 55.93 18.37 44 19510 28823 110540922
Nephropathy toxic 55.66 18.37 43 19511 27435 110542310
Disseminated intravascular coagulation 55.49 18.37 51 19503 41235 110528510
Vascular device infection 54.88 18.37 35 19519 16477 110553268
Clostridium difficile colitis 54.84 18.37 52 19502 43726 110526019
Pleural effusion 54.45 18.37 106 19448 177603 110392142
Weight increased 50.79 18.37 7 19547 419637 110150108
Stevens-Johnson syndrome 49.98 18.37 51 19503 46850 110522895
Skin fissures 48.94 18.37 38 19516 24420 110545325
Blood creatinine increased 48.79 18.37 103 19451 182786 110386959
Varicose vein 48.60 18.37 24 19530 6916 110562829
Hallucination, auditory 48.49 18.37 39 19515 26358 110543387
Neutrophil count decreased 48.35 18.37 81 19473 120860 110448885
Leukocytosis 47.58 18.37 53 19501 53775 110515970
Nasopharyngitis 46.74 18.37 7 19547 394354 110175391
Device related sepsis 46.40 18.37 24 19530 7623 110562122
Cholestasis 46.16 18.37 57 19497 64461 110505284
Candida infection 45.43 18.37 49 19505 47960 110521785
Headache 44.99 18.37 54 19500 882323 109687422
Brain oedema 44.90 18.37 40 19514 31058 110538687
Mucosal inflammation 44.73 18.37 69 19485 96072 110473673
Renal tubular necrosis 43.61 18.37 39 19515 30436 110539309
Transplant rejection 42.40 18.37 35 19519 24532 110545213
Abdominal discomfort 42.32 18.37 9 19545 393849 110175896
Drug intolerance 42.25 18.37 10 19544 406502 110163243
Febrile neutropenia 41.72 18.37 137 19417 316630 110253115
Lymphocyte count decreased 41.64 18.37 51 19503 57192 110512553
Dialysis 40.38 18.37 31 19523 19588 110550157
Bone marrow failure 39.61 18.37 50 19504 57798 110511947
White blood cell count decreased 39.43 18.37 109 19445 229281 110340464
Toxic epidermal necrolysis 38.79 18.37 49 19505 56678 110513067
Intraocular pressure increased 38.52 18.37 24 19530 10852 110558893
Paronychia 38.10 18.37 24 19530 11057 110558688
Psychotic disorder 38.05 18.37 46 19508 50891 110518854
Nephritis 36.52 18.37 19 19535 6107 110563638
Metastases to lymph nodes 35.97 18.37 26 19528 15006 110554739
Acute generalised exanthematous pustulosis 35.59 18.37 30 19524 21634 110548111
Fall 35.12 18.37 33 19521 603449 109966296
Acute respiratory distress syndrome 34.88 18.37 45 19509 53153 110516592
Autoimmune haemolytic anaemia 34.13 18.37 22 19532 10545 110559200
Pain 34.04 18.37 74 19480 954881 109614864
Systemic lupus erythematosus 33.89 18.37 3 19551 254335 110315410
Hypotension 33.76 18.37 182 19372 523667 110046078
Staphylococcal infection 33.66 18.37 51 19503 69893 110499852
Insomnia 33.50 18.37 11 19543 360579 110209166
Musculoskeletal stiffness 33.07 18.37 5 19549 279817 110289928
Pain in extremity 32.86 18.37 23 19531 487095 110082650
Cellulitis 32.47 18.37 70 19484 125946 110443799
Haemodialysis 32.17 18.37 26 19528 17693 110552052
Hepatic cytolysis 32.14 18.37 44 19510 55009 110514736
Prothrombin time prolonged 30.64 18.37 25 19529 17236 110552509
Swelling 30.41 18.37 12 19542 351029 110218716
Respiratory distress 30.05 18.37 48 19506 68826 110500919
Petechiae 29.78 18.37 28 19526 23289 110546456
Sinusitis 29.47 18.37 8 19546 296680 110273065
Gastrointestinal disorder 29.34 18.37 4 19550 241948 110327797
Weight decreased 29.14 18.37 24 19530 468033 110101712
Renal impairment 28.94 18.37 86 19468 188359 110381386
Haemoglobin decreased 28.72 18.37 103 19451 248624 110321121
Muscle spasms 28.58 18.37 7 19547 278150 110291595
Tachypnoea 28.49 18.37 35 19519 39360 110530385
Pulmonary oedema 28.36 18.37 58 19496 100601 110469144
Blood bilirubin increased 27.88 18.37 49 19505 75923 110493822
Blood alkaline phosphatase increased 27.66 18.37 47 19507 70888 110498857
Therapeutic product effect decreased 27.46 18.37 5 19549 244311 110325434
Depression 27.24 18.37 11 19543 317324 110252421
International normalised ratio increased 26.85 18.37 52 19502 86720 110483025
Interstitial lung disease 26.75 18.37 69 19485 139265 110430480
Treatment failure 26.56 18.37 8 19546 277226 110292519
Metastases to central nervous system 26.49 18.37 26 19528 22791 110546954
Dermatitis exfoliative generalised 26.30 18.37 19 19535 10953 110558792
Contusion 25.74 18.37 5 19549 233356 110336389
Subclavian artery occlusion 25.71 18.37 6 19548 167 110569578
Systemic candida 25.59 18.37 18 19536 9956 110559789
Streptococcal sepsis 25.37 18.37 14 19540 5058 110564687
Seizure 25.03 18.37 91 19463 221094 110348651
Alanine aminotransferase increased 24.63 18.37 80 19474 183693 110386052
Aspartate aminotransferase increased 24.56 18.37 73 19481 159863 110409882
Impaired healing 24.46 18.37 3 19551 196714 110373031
Linear IgA disease 24.42 18.37 13 19541 4376 110565369
Rash morbilliform 24.32 18.37 16 19538 7935 110561810
Therapeutic product effect incomplete 24.26 18.37 5 19549 223800 110345945
Malaise 23.95 18.37 52 19502 671767 109897978
Wound 23.89 18.37 6 19548 234431 110335314
Uveitis 23.84 18.37 24 19530 21686 110548059
Psychiatric decompensation 23.70 18.37 14 19540 5751 110563994
Hepatic failure 23.51 18.37 43 19511 68696 110501049
Dermatitis exfoliative 23.51 18.37 18 19536 11329 110558416
Enterococcal infection 23.26 18.37 23 19531 20343 110549402
Pneumonia 22.83 18.37 246 19308 876468 109693277
Blood culture positive 22.56 18.37 16 19538 8960 110560785
Mobility decreased 22.47 18.37 7 19547 237415 110332330
Hypersensitivity 22.43 18.37 23 19531 403975 110165770
Enterobacter pneumonia 22.38 18.37 7 19547 598 110569147
Pseudomembranous colitis 22.37 18.37 14 19540 6377 110563368
Visual acuity reduced 22.33 18.37 28 19526 32145 110537600
Bullous erysipelas 22.25 18.37 4 19550 28 110569717
Escherichia infection 21.99 18.37 24 19530 23792 110545953
Immune effector cell-associated neurotoxicity syndrome 21.31 18.37 19 19535 14763 110554982
Hepatic function abnormal 21.19 18.37 48 19506 89247 110480498
Inappropriate schedule of product administration 21.16 18.37 5 19549 203632 110366113
Acinetobacter infection 21.06 18.37 11 19543 3562 110566183
Drug ineffective 20.72 18.37 171 19383 1520369 109049376
Neutrophilic dermatosis 20.52 18.37 7 19547 785 110568960
Bacterial sepsis 20.42 18.37 16 19538 10410 110559335
Cytokine release syndrome 20.38 18.37 41 19513 70265 110499480
Death 20.33 18.37 60 19494 698809 109870936
Cytomegalovirus infection 19.82 18.37 35 19519 54409 110515336
Tachycardia 19.80 18.37 86 19468 226559 110343186
Hypoaesthesia 19.68 18.37 16 19538 314207 110255538
Clostridium difficile infection 19.61 18.37 34 19520 52095 110517650
Gastrooesophageal reflux disease 19.55 18.37 4 19550 179972 110389773
Rash erythematous 19.43 18.37 44 19510 81788 110487957
Aplasia pure red cell 19.42 18.37 15 19539 9563 110560182
Rash 19.38 18.37 226 19328 820738 109749007
Gamma-glutamyltransferase increased 19.28 18.37 37 19517 61272 110508473
Extravasation blood 19.24 18.37 6 19548 507 110569238
Haemolytic anaemia 19.17 18.37 21 19533 20899 110548846
Drug abuse 19.15 18.37 4 19550 177407 110392338
Type 2 diabetes mellitus 19.12 18.37 4 19550 177228 110392517
Hepatocellular injury 19.01 18.37 33 19521 50609 110519136
Gait disturbance 18.93 18.37 13 19541 278195 110291550
Antibiotic level above therapeutic 18.71 18.37 7 19547 1026 110568719
Wheezing 18.63 18.37 11 19543 255219 110314526
Incorrect dose administered 18.54 18.37 50 19504 103591 110466154
Acanthosis 18.50 18.37 6 19548 576 110569169
Lower respiratory tract infection 18.43 18.37 10 19544 243096 110326649

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CG02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase inhibitors
FDA MoA N0000000202 beta Lactamase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065093 beta-Lactamase Inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35625 EC 3.5.2.6 (ฮฒ-lactamase) inhibitor
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

J01CG Beta-lactamase inhibitors 2 drugs
durlobactamsulbactam

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Abscess of liver indication 27916005
Acute pyelonephritis indication 36689008 DOID:559
Peritonitis indication 48661000
Bacterial pneumonia indication 53084003 DOID:874
Haemophilus influenzae pneumonia indication 70036007
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Cholecystitis indication 76581006 DOID:1949
Infection due to Staphylococcus aureus indication 406602003
Bacterial cystitis indication 424551004
Nosocomial pneumonia indication 425464007
Ventilator-acquired pneumonia indication 429271009
Sepsis caused by Haemophilus influenzae indication 447685007
Sepsis caused by Serratia indication 449084002
Bacterial pyelonephritis indication 838353009
Staphylococcus Nosocomial Pneumonia indication
Diabetic Foot Infection indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
E. Coli Appendicitis indication
E. Coli Endometritis indication
E. Coli Complicated Appendicitis indication
Inflammatory Disease of Female Pelvic Organs indication
Complicated Skin and Skin Structure Infection indication
E. Coli Peritonitis indication
E. Coli Pelvic Inflammatory Disease indication
Bacteroides Complicated Appendicitis indication
Bacteroides Peritonitis indication
Bacteroides Appendicitis indication
Ecthyma gangrenosum off-label use 17732003
Infection of bone off-label use 111253001
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.19 acidic
pKa2 0.39 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS FOR TREATING BACTERIAL INFECTIONS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 METHODS OF TREATING BACTERIAL ILLNESSES
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 TREATMENT, IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 7129232 May 15, 2028 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10028963 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 9724353 Sept. 7, 2032 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10420841 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 11278622 March 14, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT, IN COMBINATION WITH METRONIDAZOLE, OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI)
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (AT LEAST 32 WEEKS GESTATIONAL AGE) WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 8968753 March 14, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED INTRA ABDOMINAL INFECTIONS (CIAI), IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS, IN COMBINATION WITH METRONIDAZOLE
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10376496 Sept. 9, 2034 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS 10933053 Sept. 9, 2034 TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS May 12, 2029 NEW PATIENT POPULATION
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL ZERBAXA CUBIST PHARMS LLC N206829 Dec. 19, 2014 RX POWDER INTRAVENOUS Nov. 12, 2029 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-lactamase TEM Enzyme INHIBITOR IC50 6.60 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme IC50 6.53 WOMBAT-PK
Beta-lactamase Enzyme IC50 7.82 WOMBAT-PK
Beta-lactamase Enzyme IC50 5.47 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.65 CHEMBL
Beta-lactamase 1 Enzyme IC50 6.52 DRUG MATRIX
IMI-1; IMI-1 carbapenemase Enzyme IC50 7.52 CHEMBL
Beta-lactamase Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 6.09 CHEMBL
Beta-lactamase Enzyme IC50 6.72 CHEMBL
Beta-lactamase Enzyme IC50 6.03 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL
Beta-lactamase Enzyme IC50 8 CHEMBL
Beta-lactamase Enzyme IC50 8.40 CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1 Enzyme IC50 5.16 CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC Enzyme Ki 4.13 CHEMBL
Beta-lactamase Enzyme IC50 7.02 CHEMBL
Beta-lactamase Enzyme IC50 8.70 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.96 CHEMBL
Beta-lactamase Enzyme IC50 6.62 CHEMBL
Beta-lactamase GES-13 Enzyme IC50 7.22 CHEMBL
Beta-lactamase Enzyme IC50 7.10 CHEMBL
Class D beta-lactamase Enzyme IC50 6.80 CHEMBL
Beta-lactamase Enzyme IC50 6.30 CHEMBL
Beta-lactamase Enzyme IC50 8.66 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 6.29 CHEMBL
Beta-lactamase Enzyme IC50 7.40 CHEMBL

External reference:

IDSource
D00660 KEGG_DRUG
89785-84-2 SECONDARY_CAS_RN
4020843 VANDF
C0075870 UMLSCUI
CHEBI:9421 CHEBI
TAZ PDB_CHEM_ID
CHEMBL404 ChEMBL_ID
CHEMBL1439 ChEMBL_ID
DB01606 DRUGBANK_ID
D000078142 MESH_DESCRIPTOR_UI
123630 PUBCHEM_CID
10789 IUPHAR_LIGAND_ID
6340 INN_ID
SE10G96M8W UNII
221167 RXNORM
30782 MMSL
5543 MMSL
d04404 MMSL
004398 NDDF
004399 NDDF
410931003 SNOMEDCT_US
427652008 SNOMEDCT_US
96007008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosynin Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 29 sections
Zosynin Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 29 sections
Zosynin Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 29 sections
Piperacillin and Tazobactam and Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 2 0264-3446 INJECTION, SOLUTION 250 mg INTRAVENOUS NDA 28 sections
Piperacillin and Tazobactam and Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 2 0264-3448 INJECTION, SOLUTION 375 mg INTRAVENOUS NDA 28 sections
Piperacillin and Tazobactam and Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 2 0264-3450 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 28 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9632 INJECTION, SOLUTION 0.25 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9636 INJECTION, SOLUTION 0.38 g INTRAVENOUS NDA 29 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0338-9638 INJECTION, SOLUTION 0.50 g INTRAVENOUS NDA 29 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3113 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3114 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3117 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3180 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9213 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9214 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-181 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 32 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 35369-0501 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 35369-0502 INJECTION, POWDER, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 35369-0503 INJECTION, POWDER, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 35369-0504 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-801 INJECTION, POWDER, FOR SOLUTION 0.25 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-802 INJECTION, POWDER, FOR SOLUTION 0.38 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-803 INJECTION, POWDER, FOR SOLUTION 0.50 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 44567-804 INJECTION, POWDER, FOR SOLUTION 4.50 g INTRAVENOUS ANDA 26 sections